Fibroblasts
( DrugBank: - / KEGG DRUG: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 36 | 表皮水疱症 | 8 |
36. 表皮水疱症
臨床試験数 : 163 / 薬物数 : 185 - (DrugBank : 46) / 標的遺伝子数 : 50 - 標的パスウェイ数 : 125
Showing 1 to 8 of 8 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02810951 (ClinicalTrials.gov) | July 1, 201620160701 | 13/6/201620160613 | A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB) | A Phase I/II Study of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa (RDEB) A Phase I/II Study of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessi ... | Epidermolysis Bullosa Dystrophica, Recessive | Genetic: FCX-007 | Castle Creek Biosciences, LLC. | NULL | Terminated | 7 Years | N/A | All | 6 | Phase 1/Phase 2 | United States |
| 2 | EUCTR2014-004884-19-GB (EUCTR) | 24/05/201620160524 | 18/02/201520150218 | Gene Therapy Trial in adults with Inherited Blistering Skin Disease | Phase I study of lentiviral-mediated COL7A1 gene-modified autologous fibroblasts in adults with recessive dystrophic epidermolysis bullosa (RDEB) - LENTICOL-F Phase I study of lentiviral-mediated COL7A1 gene-modified autologous fibroblastsin adults with reces ... | Recessive Dystrophic Epidermolysis Bullosa MedDRA version: 18.1;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] Recessive Dystrophic Epidermolysis Bullosa MedDRA version: 18.1;Level: PT;Classification code 100149 ... | Product Name: SIN LV Mediated ex vivo transduced autologous fibroblasts expressing codon-optimised COL7A1 Product Code: Not applicable Product Name: SIN LV Mediated ex vivo transduced autologous fibroblastsexpressing codon-optimised CO ... | King's College London | Guy's and St Thomas' NHS Foundation Trust | Not Recruiting | Female: yes Male: yes | 10 | Phase 1 | United Kingdom | ||
| 3 | NCT02493816 (ClinicalTrials.gov) | September 201520150900 | 21/5/201520150521 | Safety Study of Gene-modified Autologous Fibroblasts in Recessive Dystrophic Epidermolysis Bullosa | Phase I Study of Lentiviral-mediated COL7A1 Gene-modified Autologous Fibroblasts in Adults With Recessive Dystrophic Epidermolysis Bullosa. Phase I Study of Lentiviral-mediated COL7A1 Gene-modified Autologous Fibroblastsin Adults With Reces ... | Recessive Dystrophic Epidermolysis Bullosa | Drug: Gene-modified autologous fibroblasts | King's College London | University College, London | Completed | 17 Years | N/A | All | 5 | Phase 1 | United Kingdom |
| 4 | EUCTR2012-001815-21-PT (EUCTR) | 07/06/201320130607 | 28/03/201320130328 | A study of the safety and efficacy of ABH001 in the treatment of patients with epidermolysis bullosa who have wounds that are not healing. A study of the safety and efficacy of ABH001 in the treatment of patients with epidermolysis bullosa ... | A Multicenter, Prospective, Randomized, Open-label, Intra-patient Controlled Study of the Efficacy and Safety of ABH001 for the Treatment of Stalled Chronic Cutaneous Wounds Associated with Generalized Epidermolysis Bullosa A Multicenter, Prospective, Randomized, Open-label, Intra-patient Controlled Study of the Efficacy a ... | Epidermolysis bullosa MedDRA version: 14.1;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] Epidermolysis bullosa MedDRA version: 14.1;Level: PT;Classification code 10014989;Term: Epidermolysi ... | Product Name: Human dermal fibroblasts cultured on a bioresorbable polyglactin mesh Product Code: ABH001 INN or Proposed INN: Human dermal fibroblasts cultured on a bioresorbable polyglactin mesh Other descriptive name: Human fibroblast-derived dermal substitute, Dermagraft Product Name: Human dermal fibroblastscultured on a bioresorbable polyglactin mesh Product Code: ABH0 ... | Shire Regenerative Medicine, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 26 | France;United States;Portugal;Canada;Spain;Poland;Austria;Germany | |||
| 5 | EUCTR2012-001815-21-DE (EUCTR) | 22/05/201320130522 | 01/11/201220121101 | A study of the safety and efficacy of ABH001 in the treatment of patients with epidermolysis bullosa who have wounds that are not healing. A study of the safety and efficacy of ABH001 in the treatment of patients with epidermolysis bullosa ... | A Multicenter, Prospective, Randomized, Open-label, Intra-patient Controlled Study of the Efficacy and Safety of ABH001 for the Treatment of Stalled Chronic Cutaneous Wounds Associated with Generalized Epidermolysis Bullosa A Multicenter, Prospective, Randomized, Open-label, Intra-patient Controlled Study of the Efficacy a ... | Epidermolysis bullosa MedDRA version: 14.1;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] Epidermolysis bullosa MedDRA version: 14.1;Level: PT;Classification code 10014989;Term: Epidermolysi ... | Product Name: Human dermal fibroblasts cultured on a bioresorbable polyglactin mesh Product Code: ABH001 INN or Proposed INN: Human dermal fibroblasts cultured on a bioresorbable polyglactin mesh Other descriptive name: Human fibroblast-derived dermal substitute, Dermagraft Product Name: Human dermal fibroblastscultured on a bioresorbable polyglactin mesh Product Code: ABH0 ... | Shire Regenerative Medicine, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 26 | Portugal;United States;Spain;Austria;Australia;Germany | |||
| 6 | EUCTR2012-001815-21-AT (EUCTR) | 24/01/201320130124 | 25/01/201320130125 | A study of the safety and efficacy of ABH001 in the treatment of patients with epidermolysis bullosa who have wounds that are not healing. A study of the safety and efficacy of ABH001 in the treatment of patients with epidermolysis bullosa ... | A Multicenter, Prospective, Randomized, Open-label, Intra-patient Controlled Study of the Efficacy and Safety of ABH001 for the Treatment of Stalled Chronic Cutaneous Wounds Associated with Generalized Epidermolysis Bullosa A Multicenter, Prospective, Randomized, Open-label, Intra-patient Controlled Study of the Efficacy a ... | Epidermolysis bullosa MedDRA version: 16.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] Epidermolysis bullosa MedDRA version: 16.0;Level: PT;Classification code 10014989;Term: Epidermolysi ... | Product Name: Human dermal fibroblasts cultured on a bioresorbable polyglactin mesh Product Code: ABH001 INN or Proposed INN: Human dermal fibroblasts cultured on a bioresorbable polyglactin mesh Other descriptive name: Human fibroblast-derived dermal substitute, Dermagraft Product Name: Human dermal fibroblastscultured on a bioresorbable polyglactin mesh Product Code: ABH0 ... | Shire Regenerative Medicine, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 26 | United States;Portugal;France;Canada;Spain;Poland;Austria;Germany | |||
| 7 | EUCTR2012-001815-21-ES (EUCTR) | 18/01/201320130118 | 26/09/201220120926 | A study of the safety and efficacy of ABH001 in the treatment of patients with epidermolysis bullosa who have wounds that are not healing. A study of the safety and efficacy of ABH001 in the treatment of patients with epidermolysis bullosa ... | A Multicenter, Prospective, Randomized, Open-label, Intra-patient Controlled Study of the Efficacy and Safety of ABH001 for the Treatment of Stalled Chronic Cutaneous Wounds Associated with Generalized Epidermolysis Bullosa A Multicenter, Prospective, Randomized, Open-label, Intra-patient Controlled Study of the Efficacy a ... | Epidermolysis bullosa MedDRA version: 15.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] Epidermolysis bullosa MedDRA version: 15.0;Level: PT;Classification code 10014989;Term: Epidermolysi ... | Product Name: Human dermal fibroblasts cultured on a bioresorbable polyglactin mesh Product Code: ABH001 INN or Proposed INN: Human dermal fibroblasts cultured on a bioresorbable polyglactin mesh Other descriptive name: Human fibroblast-derived dermal substitute, Dermagraft Product Name: Human dermal fibroblastscultured on a bioresorbable polyglactin mesh Product Code: ABH0 ... | Shire Regenerative Medicine, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 25 | Portugal;United States;Spain;Austria;Australia;Germany | |||
| 8 | EUCTR2010-023121-38-GB (EUCTR) | 13/01/201120110113 | 26/11/201020101126 | A prospective placebo controlled phase II study to evaluate the use of allogeneic fibroblasts for the treatment of skin erosions in recessive dystrophic epidermolysis bulllosa. - Fibroblast cell therapy for RDEB - a phase II clinical trial A prospective placebo controlled phase II study to evaluate the use of allogeneic fibroblastsfor the ... | A prospective placebo controlled phase II study to evaluate the use of allogeneic fibroblasts for the treatment of skin erosions in recessive dystrophic epidermolysis bulllosa. - Fibroblast cell therapy for RDEB - a phase II clinical trial A prospective placebo controlled phase II study to evaluate the use of allogeneic fibroblastsfor the ... | Recessive dystropic epidermolysis bullosa | Trade Name: ICX-RHY-013 Product Name: Cultured allogeneic fibroblasts Product Code: ICX-RHY-013 INN or Proposed INN: Fibroblasts Trade Name: ICX-RHY-013 Product Name: Cultured allogeneic fibroblasts Product Code: ICX-RHY-013 INN or ... | Intercytex Ltd | NULL | Not Recruiting | Female: yes Male: yes | 25 | Phase 2 | United Kingdom |